|
Reduction
in Research and Development:
|
$ |
0.322 mln.
|
|
|
Reductions
in other SG&A costs
|
$ |
3,062 mln.
|
|
|
Total
SG&A
|
$ |
3,383 mln.
|
|
|
(slightly
above the figure set forth the Form 10K)
|
|||
|
Additional
Reductions:
|
|||
|
Reductions
in Capital Expenditure
|
$ |
0.179 mln.
|
|
Quarter
Ended January 31, 2009
|
$ | 237,000, | ||
|
Quarter
Ended April 30, 2009
|
$ | 419,000 | ||
|
Quarter
Ended July 31, 2009
|
$ | 750,000 | ||
|
Quarter
Ended October 31, 2009
|
$ | 707,000 | ||
|
Total
of cost saving against budget
|
||||
|
during
the year ended October 31, 2009
|
$ | 2,113,000 |
|
|
·
|
The
Company performed its annual impairment test according to the
pronouncements in ASC 350 “ Intangibles – goodwill and other” for FYE
October 31,
2008 by an
experienced consultant. During the quarter ended July 31, 2009, it
reviewed the assumptions used in the annual impairment test. The Company
compared the results of the annual impairment test to its current
operations and noted no material changes in the assumptions used that
require
the Company
to perform further testing for
impairment.
|
|
|
·
|
Management
noted that the shares of similar entities operating in the sectors
serviced by Martech and Colmek traded at approximating 1 to 1.2 times
annual recurring sales. Management believes that based on these
informal metrics the fair value of the individual reporting units exceeds
the current carrying value of
goodwill.
|
|
|
·
|
There
has been no change in the day to day operations of Martech and
Colmek
|
|
|
·
|
There
has been no change in the regulatory or legal environment the could have
an negative impact on the Martech or Colmek’
operations.
|
|
|
·
|
As
of the date the quarterly report of SEC Form 10Q as filed, Colmek and
Martech had secured contracts for future services (i.e, “backlog”) of
approximately $ 1,596,000 and
$ 715,000 respectively.
|
|
|
·
|
Both
Colmek and Martech project operating income and cash flows for the next 12
months.
|
|
|
·
|
The
Company has no current plans to dispose of the Martech or Colmek
at prices below their respective carrying
values.
|
|
FY2009
to July
|
FY
2008 to October
|
|||||||
| $ | $ | |||||||
|
Rent
& Utlilities
|
160,744 | 156,560 | ||||||
|
Office
Expenses
|
150,954 | 332,611 | ||||||
|
Payroll
|
1,377,743 | 2,055,700 | ||||||
|
Insurance
|
194,580 | 106,226 | ||||||
|
Professional
Fees
|
667,961 | 1,578,088 | ||||||
|
Forex
|
38,765 | 642,935 | ||||||
|
Marketing
|
279,909 | 824,593 | ||||||
|
Amortization
|
- | 198,186 | ||||||
|
Stock
Compensation
|
300,369 | 939,286 | ||||||
|
Travel
Expenses
|
134,506 | 364,870 | ||||||
|
Sale
of Asset
|
1,080 | 3,810 | ||||||
| $ | 3,306,610 | $ | 7,202,865 | |||||
|
Very
truly yours,
|
|
/s/
Louis A. Brilleman
|